Article
A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5.
Journal of virology - 1 Oct 2010
Tilton John C, Wilen Craig B, Didigu Chukwuka A, Sinha Rohini, Harrison Jessamina E, Agrawal-Gamse Caroline, Henning Elizabeth A, Bushman Frederick D, Martin Jeffrey N, Deeks Steven G, Doms Robert W
Abstract excerpt
CCR5 antagonists inhibit HIV entry by binding to a coreceptor and inducing changes in the extracellular loops (ECLs) of CCR5. In this study, we analyzed viruses from 11 treatment-experienced patients who experienced virologic failure on treatment regimens containing the CCR5 antagonist maraviroc (MVC). Viruses from one patient developed high-level resistance to MVC during the course of treatment. Although...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
